insights_auto
Why is 38I up 2.35%?
Dive Deeperchevron_right
38I:FRA
Intellia Therapeutics Inc
€10.00
arrow_upward
+2.35%(+0.23) 1D
Oct 19, 10:00:00 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 38I...
Open
€10.08
High
€10.08
Low
€10.00
Mkt. cap
1.62B
Avg. vol.
429.00
Volume
0.00
52-wk high
€24.34
52-wk low
€6.75
No. of employees
377
Open
€10.08
High
€10.08
Low
€10.00
Mkt. cap
1.62B
Avg. vol.
429.00
Volume
0.00
52-wk high
€24.34
52-wk low
€6.75
No. of employees
377
News stories
From web sources and news partners
BigGo Finance
·
11 minutes ago
Dow Falls 36 Points for Second Straight Session as Oil Rally Weighs, AI-Related Buying Provides Support
Bloomberg
·
56 minutes ago
US Stock Futures Edge Higher After Chipmaker Rally: Markets Wrap
TradingView
·
55 minutes ago
Nasdaq Jumps Past 1 Percent as VIX Swings While Dow Dips Below Its 50-Day Line
Investing.com
·
2 hours ago
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.07%
Profile
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
About Intellia Therapeutics Inc
CEOJohn Leonard
Employees377
Founded2014
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websiteintelliatx.com